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ORAL SULPHONYLUREAS IN THE MANAGEMENT OF DIABETES*
W. P. U. JACKSON, Department of Medicine, University of Cape Town
Today many thousands, even millions, of diabetics are
grateful for the existence of oral hypoglycaemic agents,
even when they merely obviate the need for injections for
a longer or shorter period. But they do more than this.
By avoiding injections the patient may also avoid insulin
allergy, bumps, fat atrophy and infection at the injection
site. More important is the greater (though not complete)
freedom from hypoglycaemic attacks, which may be par-
ticularly hazardous to patients with coronary, cerebral
or peripheral artery disease. In unintelligent patients and
those with poor vision, with parkinsonism, arthritis, hemi-
plegia, or other conditions that render injection difficult
or dangerous, the oral agents may be a real boon. Psycho-
10gicaIly they are also useful.
It is possible that both the sulphonylureas and the
diguanides have a minor rejuvenating effect on the beta-
cells of the pancreas when used, for example, in young
or mild diabetics, or prediabetics. Fajans and Conn' have
pre ented fairly convincing evidence that tolbutamide can
induce improvement in glucose tolerance in some juvenile
diabetics in their early, non-insulin-requiring phase. Occa-
sionally a sulphonylurea has been reported as effective in
treating insulin-resistance, but this is uncommon in cases
where insulin requirement exceeds 200 units a day.
Finally, and not uncommonly, an oral drug or combi-
nation may produce far better and smoother control of the
diabetes than has been attained with insulin, even when
the dose of the latter has been quite high. In the past
some people were afraid to use oral drugs on the grounds
that they might 'exhaust' the pancreatic beta-cells-this
does not happen. t
WHAT ARE SULPHONYLUREAS A ID WHAT DO THEY DO?
The early sulphonamides were observed to have hypo-
glycaemic properties and the modern sulphonylureas have
been developed from them. They are no longer true
sulphonamides nor do they exhibit antibacterial proper-
ties, though occasionally a patient may be allergic to
both groups of drug (cross-sensitivity).
Their main and only important action is to stimulate
the beta-cells of the pancreas to release insulin into the
blood stream. Plainly they can have this effect only in
a patient whose pancreas is still capable of producing
insulin. Hence they are ineffective in established, juvenile-
type, ketosis-prone diabetes at any age. Individual sulpho-
nylureas differ in chemical side-chains, duration of action,
elimination and detoxication, in some side-effects and in
potency, but their basic mode of action is identical. The
other oral hypoglycaemic drugs, the diguanides, have quite
a different mode of action.'
Who May Benefit?
Large numbers of maturity-onset diabetics have re-
'Date received: 13 November 1970.
t For further consideration of all aspects of oral drugs for diabetes see
Campbell, G. D., ed. (1969): Oral HJ'poglycaemic Drugs. London:
Academic Press.
sponded to sulphonylureas by improved control of their
blood sugar levels; many have become totally aglycosuric
for long periods. Most authorities agree that some 60-
70 0 0 of adult-onset diabetics benefit from the sulphonyl-
urea drugs. Nevertheless, apart from juvenile diabetics,
there remains a substantial proportion of apparently high-
ly suitable middle-aged non-ketotic diabetics who simply
do not respond to sulphonylureas. There is no simple
way of picking out these non-responders. You cannot be
sure until you try. -
Absolute contraindications are:
1. The presence of or liability to ketoacidosis (a single
episode of ketosis or even coma in the past is not neces-
sarily a contraindication).
2. Uncontrolled diabetes in emergencies.
3. Obesity for which diet alone has not been given a
fair chance.
Minor degrees of ketonuria do not necessarily preclude
a drug trial.
Although less likely to be effective in subjects under 40
years, sulphonylureas can be useful in .two circumstances
in young people: (a) in children after an -acute onset
of diabetes the need for insulin may remain temporarily
in abeyance, and oral drugs suffice tor a time only; and
(b) children and young adults occasionally manifest symp-
tom-free or mild diabetes. Fajans and Conn' found seve-
ral such patients while testing relatives of known diabetics
and have produced evidence of the value of tolbutamide
in some of them. In this country young, mild, sulphonyl-
urea-sensitive diabetics are particularly common in the
non-White races.
Old people may be especially sensitive to the hypogly-
caemic effect of sulphonylureas, so that caution in initi-
ating and in maintaining therapy must be used.
The longer the duration of known diabetes the less the
likelihood of adequate response to oral therapy. Never-
theless I have seen satisfactory control achieved in dia-
betics of over 20 years standing.
Previous Insulin Therapy
There is no dose relation between insulin and sulpho-
nylurea. Certainly the likelihood of good response dimi-
nishes with increasing prior insulin requirements,' so that
subjects taking more than 60 units a day are unlikely to
respond, but occasionally very large doses may be replaced
satisfactorily by a sulphonylurea. This good result is more
frequent when a combination of oral drugs is used.'
Other Considerations
The higher the previous blood sugar levels the less
likely are we to obtain a good response to sulphonylureas.
Usually the fasting level is not reduced by more than 150
mg/IOO ml, so that patients with fasting levels over 250
mg may be expected not to respond satisfactorily.' Again
this is not an invariable rule.
Sex, race and family history are unimportant in assess-
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ing probable response. Concomitant disorders, even acute
emergencies, do not contraindicate sulphonylureas pro-
vided control is maintained. The long-acting sulphonyl-
ureas (e.g. chlorproram'de) should not be given in the
presence of hepatic or renal failure. Even the short-acting
drugs must be used warily in these situations.
Obesity, Body-weight, and the Importance of Diet
The blood sugar level of overweight diabetics usually
falls rapidly when sulphonylureas are administered but
this is not the way to deal with the basic disorder. An
obese diabetic is a problem of obesity, not of diabetes.
Workers in different countries have emphasized the im-
portance of dieting and wei~ht Joss in obese patients as
the first line of treatment rather than running immediately
to the much simpler oral therapy.
Nevertheless we must all admit that the results of
dietary therapy in obese diabetics are appallingly poor,
with at most a 5 - 10% satisfactory response. One may
therefore feel reluctantly compelled to use oral therapy
(or insulin) in subjects who are still overweight after
months of unsuccessful cajolement, especially if they still
have symptoms or if they develop vascular disease. A
good argument can be made out for using a diguanide
rather than a sulphonylurea as the initial oral drug, since
the diguanides tend to cause loss of weight rather than
gain:
Even the diabetic who is within ± 5% of his ideal
weight should first of all be allowed a trial of dietary thera-
py alone unless he suffers moderately severe symptoms. It
is remarkable how frequently the symptoms do improve
and the blood sugar returns to normal or near-normal
with a simple rearrangement of dietary regimen without
change in total calorie intake and without loss of weight.
Underweight adult-onset subjects tend to respond less well
to sulphonylureas, but nevertheless often deserve a trial.
On the whole a gain in weight tends to occur during
successful treatment with sulphonylureas even in subjects
believed to have maintained their correct diet. The reason
for this phenomenon is uncertain.
Continuing and Discontinuing
The 'excellent responder' is easy. The 'partial responder'
is a problem. In some cases we must settle for partial
success as being better than we could otherwise have
achieved; in others we must not be deterred from seeking
a further improvement. We must always be willing to
try a change of sulphonylurea or to combine it with a
diguanide or if necessary to revert to insulin. We must
not be satisfied with initial control by urine sugar testing
only, because of the possibility of a raised renal threshold.
Nor should fasting blood sugar readings alone satisfy us
completely, since these may be normal despite gross
hyperglycaemia after meals.
Patients should feel well on their su\phonylureas. Fre-
quently they do in fact appear to do so despite poor
control having been achieved.
Subjects who fail to respond to sulphonylureas and to
a combination with diguanide should be given insulin,
and insulin must be substituted for tablets if the patient
continues to have symptoms, or remains or becomes
poorly controlled. We often find, after the initial antipathy
to injections, a real pleasure in the physical improvement
derived from insulin in previously incompletely controlled
subjects.
Patients may respond initially to sulphonylureas and
later become uncontrolled. Whether the drug failure is
primary or secondary, it is bad practice to continue the
drug-it is expensive, unfair and even dangerous to the
patient. Periodic checks are therefore mandatory.
Not infrequently thf opposite occurs. A patient who
really needed oral therapy for control is found later to
maintain normal blood sugar levels without the drug.
Consequently periodic attempts to reduce or stop oral
therapy should be made in well-controlled patients.
SOME GE!'.'ERAL EFFECTS OF THE SULPHO YLUREAS
Effects on Glucose Tolerance and Glycosuria
It is usually stated that sulphonylureas do not alter the
tolerance for glucose:" When effective in therapy, they
reduce the fasting blood sugar level and bring down the
whole tolerance curve in a more or less proportional
manner. Thus a normal fasting level may be obtained but
the one-hour and later levels may remain abnormally
high and postprandial glycosuria is frequent. Clear early
morning urine tests or normal fasting blood sugar levels
are therefore not enough to establish that excellent con-
trol has been achieved.
Sulphonylureas have no effect on the renal handling of
glucose and will not cause any change in renal threshold.
Relation to Vascular Disease
The effect of the sulphonylureas on vascular disease of
diabetics has been a subject for speculation and difference
of opinion. It would seem most probable' that they have
no specific effects on the development of ischaemic heart
disease, peripheral vascular disease, retinopathy, neuro-
pathy or nephropathy, apart from anything that might
be achieved by improving the control of the diabetes.
Their effect on plasma lipids has also been controversial,
but is probably unimportant.
A recent report that patients on tolbutamide may be
more liable to die from ischaemic heart disease has not
been generally accepted, and should not deter one from
using such drugs."
Effect on Endocrine Glands
Long-term effects on the pancreatic islets appear to be
beneficial rather than the reverse, and regeneration of
beta-cells has occasionally been reported.
The sulphonylureas have been shown to be goitrogenic
in animals and there have been reports suggesting an
increase in the amount of hypothyroidism in treated
patients: but further confirmation is required-our im-
pression is that this is not an important feature in our
own clinics.
Toxicity
Mild side-effects. These include gastro-intestinal upsets.
Most published series have contained up to 5% of symp-
toms including nausea, vomiting, diarrhoea, abdominal
pain, weakness, anorexia, and general malaise. The fre-
quency of such symptoms with moderate doses of sulpho-
nylureas differs little from that in placebo-treated groups
and can usually be overcome by perseverance, antacids
and taking the tablets on a full stomach. Similar reac-
tions are more frequent with the diguanides.
-
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TABLE I. SULPHONYLUREAS AVAILABLE IN SOUTH AFRICA
THE SULPHONYLUREAS AVAILABLE IN SOUTH AFRICA
The sulphonylureas available in South Africa are set
out in Table I.
Tolbutamide
Tolbutamide has become an enormously successful drug,
not only as a safe oral agent for diabetes but for various
clinical tests, in laboratory experimentation and even for
use in non-diabetic disorders. Though it is somewhat less
potent than carbutamide, chlorpropamide or tolazamide,
it carries a very small risk of toxicity-it is a safer drug
than aspirin.
Because of its short half-life, Iow fasting blood levels
of tolbutamide are found during long-term therapy. Hence
it was considered that 2 or 3 doses throughout the day
should produce better control than a single large dose;
this was believed confirmed by clinical investigation,
and consequently a split-dose regimen was recommended.
. However, it has recently been shown that single daily
doses usually, but not always, produce as good or better
control than divided doses." In any event there is seldom
need for more than 2 g (4 tablets) daily; 3 g should be
the absolute maximum.
the long-lasting effect of chlorpropamide, the hypogly-
caemia that it causes may continue for 2 or 3 days even
if the tablets are stopped. The doctor must therefore be
prepared to give repeated doses of glucose as necessary.
Mi!d hypoglycaemic reactions are more frequent than
generally realized. There is a particular risk of hypogly-
caemia during the night, leading to early morning head-
aches. With long-acting sulphonylureas between-meal
snacks may be necessary (as with insulin), and especially
a 'buffer meal' before retiring to bed at night. Such
snacks must, of course, not be allowed to add to the
daily intake of calories, but adjustment is made by
reducing the food taken at standard mealtimes.
Even the short-acting sulphonylureas are not entirely
free from danger. Occasional mild reactions occur, often
in the middle of the morning. One or two fatalities have
been reported in old people, apparently from hypogly-
caemia. Despite the short half-life of tolbutamide and
other short-acting drugs, occasional cases of severe, pro-
tracted hypoglycaemia have occurred, even with ordinary
doses, especially in non-diabetics and elderly people. Other
factors that may potentiate the hypoglycaemic effect of
sulph:::nylureas are hepatic and renal disease, malnutrition
and certain drugs including the sulphonamides, mono-





























Skin allergy also occurs in some I - 5°~ in reported
series and takes various forms, e.g. urticarial, maculo-
papular and morbilliform rashes. These usually respond
readily to antihistaminics and do not necessari;y Lqu;rc
withdrawal of the drug. Tolbutamide causes fewer cuta-
neous reactions (04 - 0.8 00 ) than ot~er commonly used
sulphonylureas.
On account of these various minor effects about 1 - 2%
of patients demand discontinuation of the drug in most
series.
More severe reactions. Photosensitivity, with a derma-
titis of the exposed areas, can be induced by all sulpho-
nylureas. The mucocutaneous syndrome (Stevens-Johnson)
and exfoliative dermatitis can be produced (rarely with
tolbutamide). These particular skin lesions may be the
forerunners of jaundice or agranulocytosis and are an
indication for stopping th~ drug. Acute attacks of por-
phyria are not induced.
Bone-marrow depression occurred with the early drug,
carb..utamide, but is rare or coincidental only with the
more recent sulphonylureas. Mild, transient and unim-
portant thrombocytopenia, however, may be found after
the inception of oral treatment.
Jaundice of cholestatic type with occasionally severe
liver-cell damage, frequently preceded by a cutaneous
hypersensitivity rash, can be produced by chlorpropa-
mide," but probably not by tolbutamide.
Pati-:nts taking chlorpropamide may become sensitive to
alcohol and develop flushing, headache, nausea and
vomiting and thoracic discomfort similar to that following
disulphuram (Antabuse) within 5 - 10 minutes of drinking
small quantities. As many as one-third of the patients
may be affected to some extent. ll Similar symptoms have
been encountered by patients taking carbutamide and
acetohexamide, and comparatively mild flushing with tol-
butamide. Glibenclamide may be free from this side-
effect. Patients taking sulphonylureas may also be more
sensitive to the cerebral depressant effect of barbiturates
and other sedatives.
Bypoglycaemia
Hypoglycaemia merits special consideration as a side-
effect of the sulphonylureas; strictly speaking it is not
so much a 'toxic' effect as an excessive amount of the
therapeutic effect that we are aiming to obtain.
Bauer'" observed several cases of 'severe hypoglycaemic
shock' (including one with acetohexamide) particularly
characterized by cerebral manifestations in older people.
Such a patient might appear to have had a stroke. Bauer
wondered whether permanent cerebral lesions may not be
produced in such individuals without recognized hypo-
glycaemic episodes. It certainly behoves the physician
to look out for minor attacks as well as major ones
in his patients.
As might be expected, hypoglycaemia is a more serious
hazard with the long-acting drugs that are cumulative,
such as carbutamide and chlorpropamide. The drug has
usually been in use for several weeks, allowing a build-up
in the blood to occur before hypoglycaemia appears.
Severe hypoglycaemia seems most likely to occur in old
people, especially when the diabetes is very mild.
Certainly the larger the dose the greater the hazard,
but even moderate doses can be dangerous. Because of
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Chlorpropamide
Chlorpropamide contains a chlorine atom attached to
its benzene ring in place of the methyl group of tolbuta-
mide. It is long-acting, cumulative and rather more power-
ful than tolbutamide in that some tolbutamide-failed
patients can be controlled with chlorpropamide.
Secondary drug failure is probably less frequent with
chlorpropamide than tolbutamide. while some patients
with secondary tolbutamide failure can be well controlled
by chlorpropamide."
Minimum and maximum effective doses are 100 and
500 mg respectively. Higher doses than this are dangerous
because of the cumulative effect. In fact the lower the
dose the safer the drug, so that a start with 250 mg or less
is recommended. The danger of severe hypoglycaemia
from higher doses is greatest in elderly, mild diabetics.
The full daily amount required should be taken in one
dose.
Acetohexamide
Acetohexamide is another non-cumulative drug with very
infrequent side-effects that has proved acceptable to dia-
betic patients. It is probably a little more potent than tol-
butamide, but because it does not show any clear-cut ad-
vantage over the earlier drugs it has not achieved such
popularity. In fact this statement applies to most of the
sulphonylureas that have come onto the market after
chlorpropamide.
The maximum maintenance dose is 1·5 g (3 tablets) a
day; usually less is needed. and a single daily dose is
usually satisfactory.
To'azamide
This drug has been said to be as potent as chlorpropa-
mide," and to be without serious toxic consequences.
However, the manufacturers admit that a fair number of
patients complain of dizziness. weakness, nervousness and
lethargy. The effective dose range appears to vary from
100 to 1 000 mg per day.
Glibenclamide
This is the most recent of the sulphonylureas and by
far the most powerful, weight for weight, being some 200
times as potent as tolbutamide as a hypoglycaemic agent
in man.IS• 19 It is remarkably non-toxic in animal tests and
probably its only side-effect in therapeutic use is an
occasional mild allergic rash. The peak concentration in
the blood after a single oral administration is reached
in about 4 hours and its effect usually lasts up to 24
hours.
It is possible that its action is slight!y different from
some of the other sulphonylureas in that it produces a
longer-lasting stimulation of insulin release from beta-cells,
and this may partly account for reports of frequent
hypoglycaemic episodes in its clinical use. Anyway, on
account of its potency, it must be used cautiously, espe-
cially in mild and elderly diabetics, and with due
attention to food coverage, as mentioned above.
Each tablet contains 5 mg of glibenclamide and the
effective dose range is between 2·5 and 20 mg daily. In
therapeutic effectiveness (as opposed to weight-for-weight
potency) it seems to be roughly on a par with chlorpro-
pamide.
Glymidine
This substance i a sulphapyrimidine and not a true
sulphonylurea, although closely related. It has no anti-
bacterial activity. Its mode of action is apparently the
same as that of the sulphonylureas. It is well tolerated
by patients and side-effects appear to be trivial. One
gram (2 tablets) daily is generally a sufficient dose. and
2 g is the absolute maximum.
Occasionally a better response can be obtained with
glymidine than with the sulphonylureas."
General Note Regarding Sulphonylurea Therap-"
Loading doses are not recommended at the commence-
ment of therapy. The total required daily amount can
always be given in a single dose in the case of chlorpro-
pamide and usually with the other drugs.
Sulphonylureas should not be used in combination with
each other, or with insulin except in very special circum-
stances under hospital supervision. The great value of
the combination of sulhonylureas with diguanides (Insoral
and Glucophage) has already been considered in this
series of articles.'
RECOMMENDATIONS FOR USE OF SULPHONYLUREAS (RESUME)
In the 'New' Patient
The newly diagnosed maturity-onset diabetic should
normally be tried on diet alone at first, even if not over-
weight. After diet fails, the choice of which oral drug
to use first is a p:crsona! matter. It should b::: remembered
that the long-acting sulphonylureas such as chlorpropa-
mide must be prescribed warily in an elderly. mild
diabetic, who may readily become hypoglycaemic. Fur-
ther, one might logically prefer a diguanide to a sulpho-
nylurea for initial trial in an overweight subject.
The Parient on Insulin
Many maturity-onset diabetics who take insulin can
be better controlled by sulphonylureas, but generally I
would recommend that the change-over be made under
hospital supervision. I believe the best method to be
adopted in general practice involves the gradual reduc-
tion of insulin dosage until none is being given or until
symptoms occur. A sulphonylurea can then be started if
it is required, but insulin must always be recommenced
if ketosis intervenes. Testing for ketonuria when heavy
glycosuria is present is an important safeguard in the
attempted change-over.
Importance of Diet
The successful reduction of the blood sugar by tablets
does not permit laxity with the diet-rather should more
stringency be striven for. Many patients who appear to
fail to respond adequately to sulphonylureas. either initio
ally or later, do so because of indiscretions in diet.
Primary Failure
Subjects who do not respond satisfactorily to the drug
within a reasonable time-usually 2 weeks-constitute
'primary failures'. On no account should the drug be
continued indefinitely in such instances; this elementary
behest is remarkably frequently ignored, usually because
trouble is not taken to check the effect of the therapy.




If oral therapy appears highly successful for several
months, with virtually normal blood sugar levels and
no glucosuria, it is possible that tbe drug is no longer
needed and it should be stopped periodicallY for this to
be checked. Bloom" in particular noted remission in 68%
of 75 maturity-onset patients after 6 weeks of tolbutamide
therapy. To continue a drug when no longer required
is unfair to the patient with regard to expense, to incon-
venience and even to the danger of toxic effects. Similarly,
attempts shou~d be made to reduce the dose periodically
even if complete discontinuation is not possible. Converse-
ly, better results may often be obtained by increasing
the dose where control is less than maximal.
Late Failure
Patients who respond well initially to an oral drug but
later become uncontrolled constitute 'secondary failures'.
This may happen with an oral drug or a combination
and illustrates the necessity for good follow-up for all
patients. Thirst and polyuria during the night are fre-
quently the first symptoms of deteriorating control.
Dealing with Drug Failures
First the diet should be checked and corrected if neces-
sary. The dose of the drug used can be increased to the
maximum recommended. If this fails, a switch can be
made to a different sulphonylurea. As a final trial of
oral therapy the combination of a sulphonylurea with
a diguanide may be used. Insulin should be started if tbis
fails, and at any stage if severe diabetic symptoms, signi-
ficant ketosis or physical deterioration develops.
SULPHONYLUREAS IN SPECIAL CIRCUMSTANCES
Sulphonylureas during pregnancy do not appear to be
harmful provided that control is maintained and that
maximum doses of the more powerful drugs (e.g. chlor-
propamide) are not used.
In acute emergencies, such as relate to infections, opera-
tions, trauma, etc., the only contraindications to sulphonyl-
ureas are inability to swallow and lack of control of the
diabetes; and certainly the appearance of ketoacidosis.
Temporary hyperglycaemia is without danger, and much
safer than the risk of hypoglycaemia from insulin in a
patient of unknown sensitivity undergoing anaesthesia.
Even if insulin becomes necessary during an infection
or other intercurrent 'stress', the sulphonylurea will almost
always become as satisfactory after the complicating dis-
order is cured as it was before. Frequently the oral drug
remains effective throughout and the management of the
patient is much simpler than with insulin.
In patients with cerebral or peripheral arteriosclerosis
the short-acting sulphonylureas are preferable to insulin
because of the lesser likelihood of hypoglycaemic reac-
tions.
Secondary diabetes associated with acromegaly, Cushing's
syndrome, corticosteroid therapy, thyrotoxicosis and cer-
tain drugs (e.g. INH, chlorothiazide and other diuretics,
and oral contraceptives) can often be controlled by sulpho-
nylureas-at least these can be tried.
Subclinical diabetes, with only an abnormal glucose-
tolerance test, and suspected prediabetes constitute an
unsolved problem. Small daily doses of a sulphonylurea
(e.g. 500 mg of tolbutamide or 100 - 125 mg of chlorpro-
pamide) are unlikely to be harmful, but whether they
will protect against the development of clinical diabetes
later is uncertain.""
CONCLUStO
The sulphonylureas are being used successfully in the
management of enormous numbers of middle-aged and
elderly diabetics, to whom they are an inestimable boon.
In these people they have taken the place of insulin, but
they are no substitute for insulin in the younger or
ketosis-prone diabetics. Initial doubts that they might even-
tually exhaust or otherwise further damage the pancreatic
islets have proved unfounded, although their effectiveness
frequently diminishes with time ('secondary failure'). Even
the safest among them is not entirely free from danger
and the doctor who prescribes them must be aware of
their limitations and of their toxic effects. No patient
should be allowed automatic and indefinite repeats of bis
APPENDtX. FLOW SHEET FOR USE OF SULPHONYLUREA
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prescription without careful supervision, nor should his
dietary regimen be allowed to slacken.
The value of the sulphonylureas has been further ex-
tended by combination with the diguanides where indi-
cated, but most authorities find no value in their combi-
nation with insulin. They have not been found to prevent,
delay or benefit vascular disease, so that they are no
panacea for the whole diabetic abnormality, any more
than is insulin. In view of their relatively physiological
mode of action in stimulating the patient's pancreas to
discharge its own insulin it is just conceivable that they
may have a place in the prevention of diabetes, but this
is quite unproven.
An abridged version of much of the contents of this
article is contained in the 'flow sheet' in the appendix.
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SOME THOUGHTS ON MEDICAL TRAINING FROM A MORBIDITY SURVEY IN
GENERAL PRACTICE IN UPINGTON*
L. MOVSOWITZ, B.SC., M.B., CH.B., General PraCliTioner, UpingTOn, CP
The general practitioner shortage, especially on our platte-
land, and the general apathy on the part of medical
graduates towards general practice, have urged me to pen
some thoughts on medical training for general practice.
I am in a single-handed general practice in Upington,
~apital of the Gordonia district. The practice caters for all
ocial strata of our three major race groups. The town
,tself at a population census taken during June 1968 was
,hown to have a total population of 27 000, comprising
7500 Whites, 14500 Coloureds and 5000 Bantu. The
-ural district, which is also partly attended to by practi-
ioners in the town, has a population of 18481 Whites,
50 995 Coloureds and 5 462 Bantu.
At the time of preparing this paper there are 8 general
)factitioners in the town, who also staff the Gordonia
-fospital of 150 beds, which is the main hospital serving
his area. We have no specialist services and administer
,naesthetics and undertake surgery within our capabilities.
>atients requiring specialist attention are mainly referred
o Cape Town.
MORBIDITY SCRVEY
)uring the period 1 July 1968 to 19 August 1968 in the
eart of our winter, which can be mild or fairly severe,
conducted a morbidity survey in my practice using the
963 classification of disease-amended version-of the
:ollege of General Practitioners.'
During these 50 days I was consulted by 2432 patients
f whom 665 (27'3%) were White, 1276 (52'5%) Coloured
nd 491 (20'2%) Bantu-a fairly representative cross-section
E the town's population. The following interesting facts
'ere noted in the patients seen:




The patients most commonly seen were aged 2 years
and under, or over 16 years. It is of note that in the 0 - 2-
year age-group the percentage of Whites seen was half
that of the Coloured and Bantu (Table I).
TABLE I. AGE INCIDENCE OF PATlE.NTS SEEN
Age White (%) Coloured (%) Bantu (%)
0- 2 10·4 21·5 22·2
2 - 6 6'3 6·8 7'5
6 - 16 12{) 8{) 8·3
Adults -1l·3 63·7 62·0
Sex Incidence
An examination of Table II shows that in the 6 - 16-year
age-group more males than females were seen among
Whites and Bantu, while among the adults there was a
noticeable preponderance of Coloured females, otherwise
the sex incidence was fairly evenly distributed.
TABLE It. SEX INCIDENCE OF PATIENTS SEEN
White Coloured Bantu
Age Male Female Male Female Male Female
0- 2 35 34 109 125 59 50
2- 6 19 23 45 42 21 16
6·16 51 29 45 57 27 14
Adults 242 232 358 455 158 146
Disease Incidence
Table III provides a detailed picture of the incidence
of the different diseases seen. In all age-groups the common
respiratory tract and gastro-intestinal ailments formed the
bulk of diseases seen. Among the Whites they constituted
217 (30'6%) of cases, among the Coloureds 424 (33'2%)
